Vyne Therapeutics Inc

詳細情報 Vyne Therapeutics Inc 企業名

VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor in preclinical development for the treatment of immuno-inflammatory indications. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.

企業情報

企業コードVYNE

会社名Vyne Therapeutics Inc

上場日Jan 25, 2018

最高経営責任者「CEO」Mr. David Domzalski

従業員数13

証券種類Ordinary Share

決算期末Jan 25

本社所在地685 Route 202/206 N., Suite 301

都市BRIDGEWATER

証券取引所NASDAQ Capital Market Consolidated

国United States of America

郵便番号08807

電話番号18007757936

ウェブサイトhttps://vynetherapeutics.com/

企業コードVYNE

上場日Jan 25, 2018

最高経営責任者「CEO」Mr. David Domzalski

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Tyler Zeronda

Chief Financial Officer, Treasurer

116.19K

-2.86%

Mr. Patrick G. Lepore

Lead Independent Director

51.47K

--

Ms. Mutya Fonte Harsch, J.D.

Chief Legal Officer, General Counsel, Secretary

42.30K

-5.45%

Mr. Steven L. Basta

Independent Director

7.45K

--

Mr. Anthony Bruno

Independent Director

--

Dr. Iain Stuart, Ph.D.

Chief Scientific Officer

--

Ms. Sharon Barbari

Independent Director

--

Dr. Christine Borowski, Ph.D.

Independent Director

--

Mr. David Domzalski

President, Chief Executive Officer, Director

--

Ms. Elisabeth A. Sandoval Little

Independent Director

--

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Tyler Zeronda

Chief Financial Officer, Treasurer

116.19K

-2.86%

Mr. Patrick G. Lepore

Lead Independent Director

51.47K

--

Ms. Mutya Fonte Harsch, J.D.

Chief Legal Officer, General Counsel, Secretary

42.30K

-5.45%

Mr. Steven L. Basta

Independent Director

7.45K

--

Mr. Anthony Bruno

Independent Director

--

Dr. Iain Stuart, Ph.D.

Chief Scientific Officer

--

収益内訳

通貨: USD更新時刻: Sun, Jul 6

FY2024

FY2023

FY2022

FY2021

FY2020

事業別USD

会社名

収益

比率

Royalty revenues

501.00K

0.00%

データなし

事業別

地域別

事業別USD

会社名

収益

比率

Royalty revenues

501.00K

0.00%

株主

更新時刻: Sun, Jun 1

株主統計

種類

株主統計

比率

Eventide Asset Management, LLC

8.37%

Access Industries, Inc.

6.70%

Citadel Advisors LLC

6.60%

Acorn Capital Advisors, LLC

4.72%

Delaware Street Capital, L.L.C.

4.18%

Other

69.43%

株主統計

比率

Eventide Asset Management, LLC

8.37%

Access Industries, Inc.

6.70%

Citadel Advisors LLC

6.60%

Acorn Capital Advisors, LLC

4.72%

Delaware Street Capital, L.L.C.

4.18%

Other

69.43%

種類

株主統計

比率

Hedge Fund

26.69%

Investment Advisor

17.90%

Corporation

6.70%

Individual Investor

2.22%

Private Equity

1.54%

Investment Advisor/Hedge Fund

1.05%

Research Firm

0.32%

Venture Capital

0.20%

Other

43.37%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

83

9.44M

56.62%

-1.32M

2025Q1

81

9.36M

56.20%

-1.38M

2024Q4

92

9.37M

63.49%

-533.87K

2024Q3

88

8.98M

61.30%

-594.32K

2024Q2

89

9.65M

66.73%

+287.65K

2024Q1

92

9.64M

67.66%

+101.95K

2023Q4

101

10.22M

72.71%

+4.63M

2023Q3

117

471.27K

14.37%

-340.06K

2023Q2

135

501.83K

15.37%

-314.68K

2023Q1

168

461.83K

16.95%

-412.21K

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

Eventide Asset Management, LLC

1.39M

8.37%

--

Mar 31, 2025

Access Industries, Inc.

1.12M

6.7%

--

Feb 14, 2025

Citadel Advisors LLC

1.10M

6.6%

-130.13K

-10.58%

Mar 31, 2025

Acorn Capital Advisors, LLC

785.94K

4.72%

+328.97K

+71.99%

Mar 31, 2025

Delaware Street Capital, L.L.C.

696.47K

4.18%

--

Sep 30, 2024

Dafna Capital Management, LLC

636.10K

3.82%

+636.10K

--

Mar 31, 2025

The Vanguard Group, Inc.

475.65K

2.85%

+521.00

+0.11%

Mar 31, 2025

Exome Asset Management LLC

462.80K

2.78%

+109.37K

+30.94%

Mar 31, 2025

Palo Alto Investors LP

445.43K

2.67%

--

Mar 31, 2025

Adage Capital Management, L.P.

344.13K

2.06%

+190.00K

+123.27%

Mar 31, 2025

詳細を見る

0.359USD

Vyne Therapeutics Inc

0.359

概要

企業名

金融